Quarterly report pursuant to Section 13 or 15(d)

Nature of Organization and Summary of Significant Accounting Policies (Details Narrative)

v3.21.2
Nature of Organization and Summary of Significant Accounting Policies (Details Narrative) - USD ($)
1 Months Ended 3 Months Ended 9 Months Ended 12 Months Ended
Mar. 10, 2021
Sep. 30, 2021
Sep. 30, 2021
Sep. 30, 2020
Mar. 31, 2020
Sep. 30, 2021
Sep. 30, 2020
Dec. 31, 2020
Product Information [Line Items]                
Number of shares issued 30,000         26,573 106,291  
Value of shares issued         $ 335,000      
Offering expense           $ 3,500,426  
Cash and cash equivalents   $ 20,650,989 $ 20,650,989     20,650,989   $ 882,870
Federally insured   250,000 250,000     250,000   250,000
Allowance for accounts receivable   4,980 4,980     4,980   0
Allowance for inventory   0 0     0   0
Deferred offering costs   $ 0 0     0   $ 153,597
Advertising costs     $ 10,694 $ 7,079   $ 86,775 $ 24,136  
One Customer [Member] | Revenue Benchmark [Member] | Customer Concentration Risk [Member]                
Product Information [Line Items]                
Concentration risk percentage     60.00% 49.00%   58.00% 31.00%  
One Customer [Member] | Accounts Receivable [Member] | Customer Concentration Risk [Member]                
Product Information [Line Items]                
Concentration risk percentage     39.00%         68.00%
IPO [Member]                
Product Information [Line Items]                
Number of shares issued   7,187,500            
Price per share   $ 4.00 $ 4.00     $ 4.00    
Value of shares issued   $ 25,250,000            
Underwriting discounts and commissions   2,406,250            
Offering expense   $ 1,093,750            
Number of shares converted   18,750,000            
Stockholders' Equity, Reverse Stock Split   one for 3.763243 reverse stock split approved by the Company’s board of directors and its shareholders.